It seems that most biotechs are seriously behind the curve when it comes to considering publicity as part of their aim to raise customer and investor awareness.   They often gauge their level of PR investment purely by the number of press releases they send out a month. Directors will ask for Read more...

Biotech companies are often terrible at communicating the benefits of their technologies and services to their clients.  So many fall into the trap of describing the background science first and leaving the potential applications and benefits until last (if at all). They are not alone.  PC Read more...